Patient examples from LIBTAYO trials

Below are examples of 3 patients with locally advanced BCC previously treated with an HHI, who saw tumors shrink (partial response) with treatment. In this trial, 23% (19 out of 84) patients had a partial response with LIBTAYO. Individual patient responses may vary.

Patient example 1

Pictured below is a facial lesion of a 77-year-old female patient. The patient had a response that lasted almost 5 months, after which the disease worsened (as shown in the 92-week image, below).

Before starting treatment
Image of a nasal lesion, before starting treatment, in a patient with locally advanced BCC
After 36 weeks
After 36 weeks of treatment: Image of a nasal lesion in a patient with locally advanced BCC
After 44 weeks
After 44 weeks of treatment: Image of a nasal lesion in a patient with locally advanced BCC
After 92 weeks
After 92 weeks of treatment: Image of a nasal lesion in a patient with locally advanced BCC
Patient example 2

Pictured below is an ear tumor of a 79-year-old male patient.

Before starting treatment
Image of an ear tumor, before starting treatment, in a patient with locally advanced BCC
After 18 weeks
After 18 weeks of treatment: Image of an ear tumor in a patient with locally advanced BCC
After 81 weeks
After 81 weeks of treatment: Image of an ear tumor in a patient with locally advanced BCC
After 104 weeks
After 104 weeks of treatment: Image of an ear tumor in a patient with locally advanced BCC

This patient's response was still ongoing at the time of data collection.

Patient example 3

Pictured below is a head lesion of a 66-year-old male patient.

Before starting treatment
Image of a head lesion, before starting treatment, in a patient with locally advanced BCC
After 9 weeks
After 9 weeks of treatment: Image of a head lesion in a patient with locally advanced BCC
After 18 weeks
After 18 weeks of treatment: Image of a head lesion in a patient with locally advanced BCC
After 101 weeks
After 101 weeks of treatment: Image of a head lesion in a patient with locally advanced BCC

This patient's response was still ongoing at the time of data collection.

Read about the most important safety information
you should know about LIBTAYO.